Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 6;4(1):46–53. doi: 10.1002/rth2.12275

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Effect of TAFI in both assays. For ECLT (A), samples from 3 individuals were used. Obtained euglobulin fractions were supplied with either buffer, PTCI (TAFI), thrombomodulin or both PTCI/TM. For t‐PA resistance CLT (B), samples from 6 individuals were used. Platelet‐free plasma was supplied with either buffer, PTCI (TAFI), thrombomodulin or both PTCI/TM. Different symbols represent individual normal plasma samples. CLT, clot lysis time; ECLT, euglobulin clot lysis time; PTCI, potato tuber carboxypeptidase inhibitor; TAFI, thrombin‐activatable fibrinolysis inhibitor; TM, thrombomodulin; t‐PA, tissue‐type plasminogen activator